Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

180,474 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study.
Oliver R, Krueger JG, Glatt S, Vajjah P, Mistry C, Page M, Edwards H, Garcet S, Li X, Dizier B, Maroof A, Watling M, El Baghdady A, Baeten D, Ionescu L, Shaw S. Oliver R, et al. Among authors: li x. Br J Dermatol. 2022 Apr;186(4):652-663. doi: 10.1111/bjd.20827. Epub 2021 Dec 27. Br J Dermatol. 2022. PMID: 34687214 Free PMC article. Clinical Trial.
Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.
Hamilton JD, Suárez-Fariñas M, Dhingra N, Cardinale I, Li X, Kostic A, Ming JE, Radin AR, Krueger JG, Graham N, Yancopoulos GD, Pirozzi G, Guttman-Yassky E. Hamilton JD, et al. Among authors: li x. J Allergy Clin Immunol. 2014 Dec;134(6):1293-1300. doi: 10.1016/j.jaci.2014.10.013. J Allergy Clin Immunol. 2014. PMID: 25482871 Free article. Clinical Trial.
A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitis.
Brunner PM, Khattri S, Garcet S, Finney R, Oliva M, Dutt R, Fuentes-Duculan J, Zheng X, Li X, Bonifacio KM, Kunjravia N, Coats I, Cueto I, Gilleaudeau P, Sullivan-Whalen M, Suárez-Fariñas M, Krueger JG, Guttman-Yassky E. Brunner PM, et al. Among authors: li x. J Allergy Clin Immunol. 2016 Jul;138(1):169-178. doi: 10.1016/j.jaci.2015.12.1323. Epub 2016 Mar 2. J Allergy Clin Immunol. 2016. PMID: 26948076
Based on Molecular Profiling of Gene Expression, Palmoplantar Pustulosis and Palmoplantar Pustular Psoriasis Are Highly Related Diseases that Appear to Be Distinct from Psoriasis Vulgaris.
Bissonnette R, Suárez-Fariñas M, Li X, Bonifacio KM, Brodmerkel C, Fuentes-Duculan J, Krueger JG. Bissonnette R, et al. Among authors: li x. PLoS One. 2016 May 6;11(5):e0155215. doi: 10.1371/journal.pone.0155215. eCollection 2016. PLoS One. 2016. PMID: 27152848 Free PMC article.
Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis.
Khattri S, Brunner PM, Garcet S, Finney R, Cohen SR, Oliva M, Dutt R, Fuentes-Duculan J, Zheng X, Li X, Bonifacio KM, Kunjravia N, Coats I, Cueto I, Gilleaudeau P, Sullivan-Whalen M, Suárez-Fariñas M, Krueger JG, Guttman-Yassky E. Khattri S, et al. Among authors: li x. Exp Dermatol. 2017 Jan;26(1):28-35. doi: 10.1111/exd.13112. Epub 2016 Aug 9. Exp Dermatol. 2017. PMID: 27304428 Free PMC article. Clinical Trial.
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.
Guttman-Yassky E, Brunner PM, Neumann AU, Khattri S, Pavel AB, Malik K, Singer GK, Baum D, Gilleaudeau P, Sullivan-Whalen M, Rose S, Jim On S, Li X, Fuentes-Duculan J, Estrada Y, Garcet S, Traidl-Hoffmann C, Krueger JG, Lebwohl MG. Guttman-Yassky E, et al. Among authors: li x. J Am Acad Dermatol. 2018 May;78(5):872-881.e6. doi: 10.1016/j.jaad.2018.01.016. Epub 2018 Jan 17. J Am Acad Dermatol. 2018. PMID: 29353025 Free PMC article. Clinical Trial.
Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab.
Brunner PM, Pavel AB, Khattri S, Leonard A, Malik K, Rose S, Jim On S, Vekaria AS, Traidl-Hoffmann C, Singer GK, Baum D, Gilleaudeau P, Sullivan-Whalen M, Fuentes-Duculan J, Li X, Zheng X, Estrada Y, Garcet S, Wen HC, Gonzalez J, Coats I, Cueto I, Neumann AU, Lebwohl MG, Krueger JG, Guttman-Yassky E. Brunner PM, et al. Among authors: li x. J Allergy Clin Immunol. 2019 Jan;143(1):142-154. doi: 10.1016/j.jaci.2018.07.028. Epub 2018 Aug 17. J Allergy Clin Immunol. 2019. PMID: 30121291 Clinical Trial.
Persistence of Inflammatory Phenotype in Residual Psoriatic Plaques in Patients on Effective Biologic Therapy.
Mashiko S, Edelmayer RM, Bi Y, Olson LM, Wetter JB, Wang J, Maari C, Saint-Cyr Proulx E, Kaimal V, Li X, Salte K, Garcet S, Kannan AK, Huang SM, Cao X, Liu Z, Krueger JG, Sarfati M, Bissonnette R, Smith KM. Mashiko S, et al. Among authors: li x. J Invest Dermatol. 2020 May;140(5):1015-1025.e4. doi: 10.1016/j.jid.2019.09.027. Epub 2019 Nov 9. J Invest Dermatol. 2020. PMID: 31715177 Free article.
180,474 results
You have reached the last available page of results. Please see the User Guide for more information.